Samitib contains Imatinib Mesylate, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. Imatinib inhibits specific abnormal tyrosine kinases, particularly BCR-ABL, which is associated with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

It is also used for selected cases of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and gastrointestinal stromal tumors (GIST) with appropriate molecular abnormalities.

What is Imatinib Mesylate?

Imatinib Mesylate is an oral targeted anticancer medicine that inhibits several tyrosine kinases, including BCR-ABL, KIT (CD117), and PDGF receptors.

By blocking these signaling pathways, Imatinib can interfere with the growth and proliferation of susceptible malignant cells.

Benefits and Uses of Samitib

Samitib (Imatinib Mesylate) may be prescribed for:

• Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
• Selected cases of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Gastrointestinal stromal tumors (GIST) with appropriate KIT abnormalities
• Selected myelodysplastic/myeloproliferative diseases associated with specific PDGF receptor abnormalities
• Other selected malignancies involving susceptible tyrosine kinase abnormalities

The exact indication depends on the patient’s diagnosis and molecular characteristics.

Dosage Guidelines

The dosage of Imatinib Mesylate varies according to the disease, treatment response, age, and individual patient factors.

• Take Samitib exactly as prescribed by the treating physician.
• Imatinib is generally administered orally, usually once daily, although some treatment regimens may use divided doses.
• It is generally recommended to take Imatinib with a meal and a large glass of water to help reduce gastrointestinal irritation.
• Take the tablets according to the product instructions.
• Do not change the dose or stop treatment without medical advice.
• Regular blood counts and other laboratory tests may be required during treatment.

Wholesale & Supply

Onco India International can support wholesale and bulk pharmaceutical supply of Samitib (Imatinib Mesylate) for eligible markets and pharmaceutical procurement requirements.

Bulk supply may be suitable for:

• Pharmaceutical distributors
• Hospitals and healthcare institutions
• Oncology distributors
• Hematology-focused healthcare suppliers
• International pharmaceutical buyers
• Licensed importers and exporters
• Healthcare procurement organizations

Packaging, minimum order quantities, documentation, and availability may vary according to market requirements.

Buying Imatinib Mesylate Online

When sourcing Samitib or other Imatinib Mesylate products, buyers should verify the strength, dosage form, manufacturer, batch information, packaging, and applicable quality documentation.

Imatinib is a prescription anticancer medicine. Pharmaceutical products should be obtained through authorized and appropriately licensed suppliers and used under qualified medical supervision.

Reviews

Individual responses to Imatinib may vary depending on the underlying disease, molecular characteristics, treatment regimen, disease stage, and patient-specific factors.

For pharmaceutical procurement, important considerations include product quality, manufacturing standards, documentation, packaging integrity, and supply reliability.

Quality Assurance

Quality assurance is essential for targeted oncology medicines such as Imatinib Mesylate. Products should be manufactured, tested, packaged, and stored according to applicable pharmaceutical quality and regulatory requirements.

Relevant documentation, including available product specifications, certificates, batch information, and package inserts, can be requested where applicable.

Frequently Asked Questions

What is Samitib used for?

Samitib contains Imatinib Mesylate and is used for several cancers and blood disorders, particularly Philadelphia chromosome-positive CML and certain GISTs.

What type of medicine is Imatinib Mesylate?

Imatinib is a tyrosine kinase inhibitor (TKI) and targeted anticancer medicine.

How does Imatinib work?

Imatinib blocks specific tyrosine kinase proteins, including BCR-ABL and KIT, interfering with signaling pathways that promote the growth and survival of susceptible cancer cells.

Is Imatinib used for leukemia?

Yes. Imatinib is an established targeted treatment for several forms of Philadelphia chromosome-positive leukemia, particularly CML and selected cases of Ph+ ALL.

Is Imatinib used for GIST?

Yes. Imatinib is used for certain GISTs, particularly tumors with susceptible KIT or related tyrosine kinase abnormalities.

How is Imatinib administered?

Imatinib is taken orally. The dosage and frequency depend on the specific disease and prescribed treatment regimen.

What are common side effects of Imatinib?

Possible adverse effects include nausea, vomiting, diarrhea, muscle cramps, fatigue, edema, rash, abdominal discomfort, and changes in blood counts. Liver abnormalities and other serious adverse effects can also occur.

Does Imatinib require regular monitoring?

Yes. Depending on the indication, physicians may monitor complete blood counts, liver function, kidney function, treatment response, and disease-specific molecular or cytogenetic markers.

Can Imatinib interact with other medicines?

Yes. Imatinib can interact with medicines that affect CYP3A4 and with other drugs that may alter Imatinib exposure. Patients should inform their healthcare professional about all medicines and supplements they use.

Conclusion

Samitib (Imatinib Mesylate) is a targeted tyrosine kinase inhibitor used in the treatment of several malignancies and hematologic disorders driven by specific kinase abnormalities. Its important applications include Philadelphia chromosome-positive CML, selected Ph+ ALL, and certain GISTs.

Because treatment selection, dosage, and monitoring depend on the specific disease and molecular characteristics, Imatinib should be prescribed and monitored by an appropriate oncology or hematology specialist.